摘要
前言:阿尔茨海默病(AD)在大脑中的病理过程可能比其第一次临床症状和AD症状的出现早20-30年。痴呆症的其他主要原因的症状。因此,提高对本病的早期诊断和鉴别诊断至关重要。事件相关电位(Erp)测量脑电图显示AD的诊断潜力。 目的:比较P 300和N 200电位及反应时间(RT)与脑脊液(CSF)中常用蛋白质生物标志物的效率,包括淀粉样β肽(Aβ1-42),总τ(t-τ),苏氨酸181磷酸化的τ蛋白(p-Tu 181),丝氨酸199磷酸化的τ蛋白(p-Tu 199),苏氨酸231磷酸化的τ蛋白。在轻度认知功能障碍(MCI)和AD患者中鉴别诊断AD的P-Tu 231和VILIP-1。研究对象:49例AD患者,28例MCI患者,4例健康对照者和16例其他主要病因痴呆患者。 结果:ERP(P300RT、N200RT、P 300计数和N 200计数)与蛋白CSF标志物呈中度至强相关性。我们证实了先前的中强相关观测。在ERP与神经心理测试之间,发现AD患者经乙酰胆碱酯酶抑制剂治疗后P 300潜伏期缩短,RT缩短。利用ERP和RT建立d的预测模型在MCI患者中,发现56.3%的MCI患者存在AD的高风险。病理水平为Aβ1-42的MCI患者有PRO。延长P 300潜伏期,提示联合应用ERP和CSF蛋白生物标志物可提高MCI患者对AD的鉴别诊断。此外,研究结果还表明F P 300潜伏期在鉴别AD和FTD患者中的应用。 结论:我们的数据为提高AD的鉴别诊断提供了可能的解决方案,并揭示了csf蛋白标志物t-τ、p-tu 181、p-tu 199、p-tu 231的诊断效率。在临床实践中加入ERP可以改善VILIP-1。
关键词: 阿尔茨海默病,淀粉样β肽,生物标志物,诱发电位,τ蛋白,脑脊液。
Current Alzheimer Research
Title:Event-related Potentials Improve the Efficiency of Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer’s Disease
Volume: 15 Issue: 13
关键词: 阿尔茨海默病,淀粉样β肽,生物标志物,诱发电位,τ蛋白,脑脊液。
摘要: Introduction: The pathological process of Alzheimer's disease (AD) in the brain likely begins 20-30 years earlier than the emergence of its first clinical symptoms and symptoms of AD often overlap with the symptoms of other primary causes of dementia. Therefore, it is crucially important to improve early and differential diagnosis of the disease. Event-related potentials (ERP) measured non-invasively by electroencephalography have shown diagnostic potential in AD.
Aims: The aim of this study was to compare the efficiency of P300 and N200 potentials and reaction time (RT) with commonly used protein biomarkers measured in the cerebrospinal fluid (CSF), including amyloid β peptide (β1-42), total tau (t-tau), tau protein phosphorylated at threonine 181 (p-tau181), tau protein phosphorylated at serine 199 (p-tau199), tau protein phosphorylated at threonine 231 (p-tau231), and visinin-like protein 1 (VILIP-1) in differential diagnosis of AD in mild cognitive impairment (MCI) and AD patients.
Subjects: The study involved 49 AD patients, 28 patients with MCI, 4 healthy control subjects and 16 patients with other primary causes of dementia.
Results: ERP (P300RT, N200RT, P300 counting and N200 counting) showed a moderate to strong correlation with protein CSF biomarkers. We confirmed previous observations of moderate to strong correlation between ERP and neuropsychological testing and showed that P300 latency and RT are shortened in AD patients on therapy with acetylcholinesterase inhibitors. Using ERP and RT, a predictive model for determination of AD likelihood in MCI patients was developed, detecting 56.3% of MCI patients with high risk for development of AD in our cohort. MCI patients with pathological levels of Aβ1-42 had prolonged P300 latency, indicating that a combination of ERP and CSF protein biomarkers could improve the differential diagnosis of AD in MCI patients. Additionally, the results suggested the potential of P300 latency in differentiating AD and FTD patients.
Conclusion: Our data provide possible solutions for improvement of differential diagnosis of AD, and reveal that the diagnostic efficiency of CSF protein biomarkers t-tau, p-tau181, p-tau199, p-tau231 and VILIP-1 could be improved by adding ERP in clinical practice.
Export Options
About this article
Cite this article as:
Event-related Potentials Improve the Efficiency of Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer’s Disease, Current Alzheimer Research 2018; 15 (13) . https://dx.doi.org/10.2174/1567205015666180911151116
DOI https://dx.doi.org/10.2174/1567205015666180911151116 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnology: A Novel Approach for Drug Development in Health Care System
Current Nanomaterials ABAD: A Potential Therapeutic Target for Aβ-Induced Mitochondrial Dysfunction in Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design The LDL-Receptor and its Molecular Properties: From Theory to Novel Biochemical and Pharmacological Approaches in Reducing LDL-cholesterol
Current Medicinal Chemistry Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design The Role of Autophagy on the Survival of Dopamine Neurons
Current Topics in Medicinal Chemistry Preface: Highlights of Recent Progress in Alzheimers Disease Research [ Hot Topics in Alzheimers Disease Research (Guest Editor: Debomoy K. Lahiri)]
Current Drug Targets Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research Potential Protective Effect of Dl-3-n-butylphthalide on Chronic Cerebral Ischemia Brain Injury
CNS & Neurological Disorders - Drug Targets Conference Report: 183rd American Association for the Advancement of Science Annual Meeting, Boston MA, USA Feb 16-20, 2017: "Serving Society through Science Policy"
CNS & Neurological Disorders - Drug Targets Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review
Letters in Drug Design & Discovery The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus
Current Proteomics Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) TAU Aggregation is a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research Decreased Cerebral Perfusion and Oxidative Stress Result in Acute and Delayed Cognitive Impairment
Current Neurovascular Research Therapeutic Potential of γ -Secretase Inhibitors and Modulators
Current Topics in Medicinal Chemistry Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology